Skip to main content

Table 1 Molecular, functional characteristics and source of origin of the indicated cell lines

From: Evolving neoantigen profiles in colorectal cancers with DNA repair defects

Sample

Microsatellite status

Altered MSI markers

Genome evolvability

Split ratio

In vitro doubling time

Growth rate

Source

C10

Stable

Stable

0.34

2.33

0.30

ECACC

C106

Stable

Stable

0.35

2.50

0.28

ECACC

C125PM

Stable

Stable

0.34

2.37

0.29

ECACC

C32

Stable

Stable

0.18

1.54

0.45

ECACC

C70

Stable

Stable

0.4

2.76

0.25

ECACC

C75

Stable

Stable

0.36

2.46

0.28

ECACC

C99

Stable

NA

NA

NA

NA

ECACC

CACO2

Stable

Stable

0.26

1.83

0.38

ATCC

CAR1

Stable

Stable

0.36

2.47

0.28

JCRB

CCK81

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.34

2.53

0.27

RIKEN

CL14

Stable

NA

NA

NA

NA

DSMZ

COCM1

Stable

Evolving

0.3

2.34

0.30

JCRB

COGA1

Unstable

bat26-mono27-nr24

NA

NA

NA

NA

Dr. Hubera

COGA2

Stable

Stable

0.32

2.22

0.31

Dr. Hubera

COGA5

Stable

Stable

0.20

1.69

0.41

Dr. Hubera

COGA8

Stable

Stable

0.22

1.67

0.41

Dr. Hubera

COLO201

Stable

NA

NA

NA

NA

ATCC

COLO94H

Stable

Stable

0.45

2.81

0.25

CLS

DIFI

Stable

NA

NA

NA

NA

Dr. Baselgab

DLD1

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.07

0.98

0.71

NCI60

HCA24

Stable

Evolving

0.33

2.22

0.31

ECACC

HCA46

Stable

Stable

0.4

2.41

0.29

ECACC

HCC2998

Stable

Stable

0.34

2.33

0.30

NCI60

HDC114

Stable

Evolving

0.23

1.69

0.41

DKFZc

HDC142

Stable

Evolving

0.35

2.42

0.29

DKFZc

HDC82

Stable

NA

NA

NA

NA

DKFZc

HRA16

Stable

NA

NA

NA

NA

ECACC

HROC24

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.16

1.23

0.56

Dr. Linnebacherd

HROC32

Stable

Stable

0.62

6.07

0.11

Dr. Linnebacherd

HROC334

Stable

Stable

0.45

2.83

0.24

Dr. Linnebacherd

HROC39

Stable

Stable

0.5

3.92

0.18

Dr. Linnebacherd

HROC69

Stable

Stable

0.33

2.26

0.31

Dr. Linnebacherd

HT115

Stable

Evolving

0.24

1.78

0.39

ECACC

HT29

Stable

Stable

0.16

1.38

0.50

NCI60

HT55

Stable

Stable

0.33

2.21

0.31

ECACC

LIM1215

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.15

1.24

0.56

Dr. Whiteheade

LIM2099

Stable

Stable

0.33

2.26

0.31

Dr. Whiteheade

LOVO

Unstable

nr21-bat25-mono27-nr24

NA

NA

NA

NA

ATCC

LS180

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.25

1.90

0.37

ATCC

LS411N

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.32

2.29

0.30

ATCC

MDST8

Stable

Stable

0.15

1.31

0.53

ECACC

NCIH716

Stable

NA

NA

NA

NA

ATCC

OUMS23

Stable

Stable

0.26

1.70

0.41

JCRB

OXCO3

Stable

Stable

0.23

1.76

0.39

Dr. Cerundolof

RW7213

Stable

Stable

0.4

2.60

0.27

Dr. Arangog

SNU1040

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.54

4.14

0.17

KCLB

SNU1181

Stable

Stable

0.62

4.65

0.15

KCLB

SNU1235

Stable

Evolving

0.35

2.33

0.30

KCLB

SNU1411

Stable

Evolving

0.44

2.76

0.25

KCLB

SNU1460

Stable

NA

NA

NA

NA

KCLB

SNU1684

Unstable

bat26-nr21-bat25-mono27-nr24

NA

NA

NA

NA

KCLB

SNU175

Unstable

bat26-nr21-bat25-mono27

NA

NA

NA

NA

KCLB

SNU283

Stable

NA

NA

NA

NA

KCLB

SNU479

Stable

NA

NA

NA

NA

KCLB

SNU81

Stable

Evolving

0.42

2.33

0.30

KCLB

SNU977

Stable

Stable

0.42

2.71

0.26

KCLB

SNUC1

Stable

NA

NA

NA

NA

KCLB

SW1417

Stable

NA

NA

NA

NA

ATCC

SW1463

Stable

NA

NA

NA

NA

ATCC

SW480

Stable

Stable

0.18

1.64

0.42

ATCC

SW837

Stable

Stable

0.27

2.07

0.34

ATCC

V411

Stable

Stable

0.22

1.91

0.36

Dr. Markovitzh

V481

Unstable

bat26-nr21-bat25-mono27-nr24

NA

NA

NA

NA

Dr. Markovitzh

WIDR

Stable

NA

NA

NA

NA

Dr. Bernardsi

  1. Non-commercial cell lines were provided by (a) Dr. L. A. Huber, Cell Biology/Biocenter, Medical University of Innsbruck, Innsbruck, Austria; (b) Dr. Baselga, Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’ Hebron University Hospital, Barcelona, Spain; (c) Dr. M. Schawb, Division of Tumour Genetics - B030 German Cancer Research Center (DKFZ), Heidelberg, Germany; (d) Dr. M. Linnebacher, Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany; (e) Dr. R.H. Whitehead, Depts of Medicine, Cell and Developmental Biology and Cancer Biology, Vanderbilt University, Nashville, USA; (f) Dr. V. Cerundolo, Nuffield Dept of Clinical Medicine, John Radcliffe Hospital, Oxford, UK; (g) Dr. D. Arango, Group of Molecular Oncology, Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d’Hebron, Barcelona, Spain; (h) Dr. S. Markovitz, Case Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Case Western Reserve University, Cleveland, USA; (i) Dr. R. Bernards, Division of Molecular Carcinogenesis B7, Netherlands Cancer Institute, Amsterdam, The Netherlands.